These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 30403305)

  • 41. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.
    Jacobs MR
    Clin Microbiol Infect; 2001 Nov; 7(11):589-96. PubMed ID: 11737083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling.
    Nicolau DP
    J Infect Chemother; 2003 Dec; 9(4):292-6. PubMed ID: 14691648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review.
    Hodiamont CJ; van den Broek AK; de Vroom SL; Prins JM; Mathôt RAA; van Hest RM
    Clin Pharmacokinet; 2022 Aug; 61(8):1075-1094. PubMed ID: 35754071
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves.
    Brentnall C; Cheng Z; McKellar QA; Lees P
    Res Vet Sci; 2013 Jun; 94(3):687-94. PubMed ID: 23415880
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
    Pai MP; Neely M; Rodvold KA; Lodise TP
    Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New dosing strategies for antibacterial agents in the neonate.
    de Hoog M; Mouton JW; van den Anker JN
    Semin Fetal Neonatal Med; 2005 Apr; 10(2):185-94. PubMed ID: 15701583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens.
    Maglio D; Nicolau DP
    Methods Find Exp Clin Pharmacol; 2004 Dec; 26(10):781-8. PubMed ID: 15672121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
    Cusumano JA; Klinker KP; Huttner A; Luther MK; Roberts JA; LaPlante KL
    Am J Health Syst Pharm; 2020 Jul; 77(14):1104-1112. PubMed ID: 32537644
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients.
    Turner RB; Kojiro K; Shephard EA; Won R; Chang E; Chan D; Elbarbry F
    Pharmacotherapy; 2018 Dec; 38(12):1174-1183. PubMed ID: 30362592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ
    J Chemother; 1999 Dec; 11(6):426-39. PubMed ID: 10678784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
    Segreti J; Jones RN; Bertino JS
    J Ocul Pharmacol Ther; 2012 Feb; 28(1):3-11. PubMed ID: 21999341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.
    Rubino CM; Bradley JS
    Paediatr Drugs; 2007; 9(6):361-9. PubMed ID: 18052406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Zhou YF; Tao MT; He YZ; Sun J; Liu YH; Liao XP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038275
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation.
    Peris-Marti JF; Borras-Blasco J; Rosique-Robles JD; Gonzalez-Delgado M
    J Clin Pharm Ther; 2004 Feb; 29(1):65-70. PubMed ID: 14748900
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.
    Stockmann C; Roberts JK; Yu T; Constance JE; Knibbe CA; Spigarelli MG; Sherwin CM
    Expert Rev Anti Infect Ther; 2014 Nov; 12(11):1371-88. PubMed ID: 25301231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices.
    Heintz BH; Thompson GR; Dager WE
    Ann Pharmacother; 2011 Nov; 45(11):1338-45. PubMed ID: 22010003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Do We Bury Antibacterials When Launching? Cefaclor Example.
    Tomić Z; Tomas A; Vukmirović S; Mikov M; Horvat O; Tomić N; Sabo A
    J Pharm Sci; 2016 Mar; 105(3):1295-300. PubMed ID: 26886327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.